Bioinformatics, Convergence Science, and Systems Biology最新文献

筛选
英文 中文
Abstract 2442: Assessing how macrophages attain distinct iron handling phenotypes in a tumor via a mathematical model 摘要:通过数学模型评估巨噬细胞如何在肿瘤中获得不同的铁处理表型
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-2442
L. Vieira, Joseph Masison, Jacqueline Adams, S. Torti, R. Laubenbacher, Julia Chifman
{"title":"Abstract 2442: Assessing how macrophages attain distinct iron handling phenotypes in a tumor via a mathematical model","authors":"L. Vieira, Joseph Masison, Jacqueline Adams, S. Torti, R. Laubenbacher, Julia Chifman","doi":"10.1158/1538-7445.SABCS18-2442","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-2442","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131333247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Abstract 1646: Beyond BRCA: Discovery of novel drivers of homologous recombination deficiencies in cancer 1646:超越BRCA:发现癌症中同源重组缺陷的新驱动因素
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-1646
Nidhi Sahni, D. McGrail, Yongsheng Li, G. Mills, S. Yi
{"title":"Abstract 1646: Beyond BRCA: Discovery of novel drivers of homologous recombination deficiencies in cancer","authors":"Nidhi Sahni, D. McGrail, Yongsheng Li, G. Mills, S. Yi","doi":"10.1158/1538-7445.AM2019-1646","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-1646","url":null,"abstract":"Since the discovery of BRCA1 and BRCA2 mutations as cancer risk factors, we have gained much understanding of their role in maintaining genomic stability through homologous recombination (HR) DNA repair. However, mutations in BRCA1/2 and other classical HR proteins such as RAD51 and PALB2 only identify 10-20% of TCGA patients who display HR deficiencies, indicating that we do not understand the vast majority of HR defects. Here, we leveraged the abundance of molecular characterization from TCGA patients for network analysis to fill this knowledge void. We discovered that over half of HR deficiencies originate outside of canonical DNA damage response genes, with particular enrichment for RNA binding proteins (RBPs). Experimental techniques validated over 90% of our predictions in a panel of 50 genes tested by siRNA, as well as 30/31 additional engineered mutations identified in TCGA patients. We further cross-validated these findings in independent patient cohorts, finding that the identified RNA processing mutations again enriched for HR deficient patients to an equal or greater degree than mutations in DNA damage genes. Using a series of experimental approaches, including protein interactome screening, RNA sequencing, and quantitative imaging cytometry, we probed how loss of RBP function induced global DNA damage response rewiring, including changes in RNA splicing, protein-protein interactions, and recruitment of repair factors to DNA damage sites. Clinically, defects in HR are known to promote cancer initiation, but also sensitize cells to targeted therapies such as PARP inhibition. We found that depletion RBPs from PARP-resistant triple-negative breast cancer cells induced sensitivity to multiple PARP inhibitors, indicating that this could identify new cohorts of patients who may benefit from PARP inhibition, beyond the small number of BRCA1/2-mutant patients. Moreover, we find that the identified RBP genes are significantly enriched for genes associated with cancer risk identified through GWAS. In patients, HR deficiencies were not equally distributed across all demographics, so preferential screening of those most at risk could further heighten this benefit. Thus, these novel drivers may show clinical relevance both for treatment stratification and for identifying individuals at high risk for cancer development to improve patient outcomes. Taken together, this exhaustive study greatly expands our repertoire of known drivers of HR deficiencies and mechanisms of damage repair, which may impact research from the most basic biology studies to clinical screening and stratification. Citation Format: Nidhi Sahni, Daniel McGrail, Yongsheng Li, Gordon Mills, Song (Stephen) Yi. Beyond BRCA: Discovery of novel drivers of homologous recombination deficiencies in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abs","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132051461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 5096: Exploring novel prognostic genetic markers using elastic-net regularization and association rule mining in HER2-negative metastatic gastric cancer patients 5096:利用弹性网正则化和关联规则挖掘在her2阴性转移性胃癌患者中探索新的预后遗传标记
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-5096
Sejung Park, W. Kwon, Inhye Jeong, Hyun Jeong Kim, Jong Soo Hong, Jae Young Kim, Jingmin Che, C. Nam, H. Chung, S. Rha
{"title":"Abstract 5096: Exploring novel prognostic genetic markers using elastic-net regularization and association rule mining in HER2-negative metastatic gastric cancer patients","authors":"Sejung Park, W. Kwon, Inhye Jeong, Hyun Jeong Kim, Jong Soo Hong, Jae Young Kim, Jingmin Che, C. Nam, H. Chung, S. Rha","doi":"10.1158/1538-7445.SABCS18-5096","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-5096","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"65 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134005355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 4242: Systematic transcriptome analysis of small cell carcinoma of esophagus suggests a possibility for immunotherapy 摘要食道小细胞癌的系统转录组分析提示免疫治疗的可能性
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-4242
Qi Zhao, Yanxing Chen, Yingnan Wang, Qi-Nian Wu, Hui Sheng, Jia-Jia Hu, Yun-xin Lu, Zexian Liu, Zhixiang Zuo, Feng Wang, R. Xu
{"title":"Abstract 4242: Systematic transcriptome analysis of small cell carcinoma of esophagus suggests a possibility for immunotherapy","authors":"Qi Zhao, Yanxing Chen, Yingnan Wang, Qi-Nian Wu, Hui Sheng, Jia-Jia Hu, Yun-xin Lu, Zexian Liu, Zhixiang Zuo, Feng Wang, R. Xu","doi":"10.1158/1538-7445.SABCS18-4242","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-4242","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134088763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Abstract 3394: Diagnosis of intrahepatic metastasis (IM) and multi-entric (MC) carcinogenesis by novel mutational signature in patients with multiple and recurrent hepatocellular carcinomas 3394:通过新的突变特征诊断多发性和复发性肝细胞癌患者的肝内转移(IM)和多中心(MC)癌变
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-3394
P. Yang, Shilei Bai, Yanpeng Zhang, Zhi-fang Xie, Zhangjun Cheng, Jie Yang, Jun Li, Jia-Quan Wang, Z. Lei, Yong Xia, Kui Wang, Zheng Li, Bao-hua Zhang, X. Wan, Meng‐chao Wu, F. Shen
{"title":"Abstract 3394: Diagnosis of intrahepatic metastasis (IM) and multi-entric (MC) carcinogenesis by novel mutational signature in patients with multiple and recurrent hepatocellular carcinomas","authors":"P. Yang, Shilei Bai, Yanpeng Zhang, Zhi-fang Xie, Zhangjun Cheng, Jie Yang, Jun Li, Jia-Quan Wang, Z. Lei, Yong Xia, Kui Wang, Zheng Li, Bao-hua Zhang, X. Wan, Meng‐chao Wu, F. Shen","doi":"10.1158/1538-7445.SABCS18-3394","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-3394","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126583124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 1651: Utilization of an ensemble approach for identification of driver fusions in pediatric cancer 摘要:利用集成方法识别儿童癌症的驱动融合
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-1651
S. LaHaye, Kyle Voytovich, James R. Fitch, S. McGrath, Anthony B. Miller, Amy N Wetzel, V. Magrini, E. Mardis, R. Wilson, P. White, C. Cottrell
{"title":"Abstract 1651: Utilization of an ensemble approach for identification of driver fusions in pediatric cancer","authors":"S. LaHaye, Kyle Voytovich, James R. Fitch, S. McGrath, Anthony B. Miller, Amy N Wetzel, V. Magrini, E. Mardis, R. Wilson, P. White, C. Cottrell","doi":"10.1158/1538-7445.AM2019-1651","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-1651","url":null,"abstract":"Pediatric cancers, which make up ~1% of cancer diagnoses each year, comprise distinct genomic landscapes compared to adult cancers. Pediatric cancers typically exhibit a “quiet” genome with a reduced number of somatic mutations compared to adult tumors, which tend to carry a high mutational burden. In addition, pediatric tumors are often associated with fusion events, including fusions that involve potentially targetable kinases, as well as transcription factors which can often be targeted downstream. Fusion events can occur through chromosomal rearrangements, large deletions, or insertions. These events can lead to dysregulated gene expression, and can often become a driving event in pediatric cancer. Sensitive and specific detection of these fusion events through the utilization of RNA-seq data has proven to be a difficult task, given the complexities in tumor cellularity and clonality, and the numerous false positive identifications that are typically output from single fusion callers. Additionally, there are confounding issues surrounding memory usage and compute time required for certain fusion calling algorithms. The Institute for Genomic Medicine at Nationwide Children’s Hospital has implemented an ensemble approach, utilizing 7 fusion callers: FusionMap, JAFFA, STAR-Fusion, SOAPfuse, FusionCatcher, MapSplice, and TopHat-Fusion. This approach allows us to identify fusions that have been called by at least 2 of the above algorithms, and also allows for a prioritization approach based on the number of callers that have identified a specific fusion. We have employed this approach on 67 pediatric cancer cases that we have analyzed in a collaborative Institutional Review Board approved protocol which encompasses scientists, genetic counselors, oncologists, and pathologists at Nationwide Children’s Hospital. These cases are comprised of 52 central nervous system (CNS) tumors, 13 solid tumors, and 1 hematologic tumor, to date. To analyze these cases for fusion events, total RNA-seq with ribodepletion was performed on RNA, extracted from either flash frozen or Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples, to generate libraries that were sequenced using 150bp paired-end reads. Through the employment of our ensemble fusion calling approach and a manual knowledge based filtering strategy, we have currently identified 18 clinically meaningful fusions, all of which we have confirmed in a CAP/CLIA laboratory. We have identified both known and novel fusion events, of which several have provided diagnostic value and/or provided targeted treatment options for patients. In conclusion, this method has the potential to offer a streamlined approach to uncover driver fusions in cancer, while also providing additional diagnostics and an opportunity to identify targeted treatment options for patients in a clinical setting. Citation Format: Stephanie LaHaye, Kyle Voytovich, James Fitch, Sean McGrath, Anthony Miller, Amy Wetzel, Vincent Magrini, Elaine R.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130738731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 677: A precision dosing application for prostate cancer chemotherapy 677:精准给药在前列腺癌化疗中的应用
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-677
Claire Villettte, H. Mistry, F. Ortega, D. Orrell, F. Brightman, J. L. Millén, C. Chassagnole
{"title":"Abstract 677: A precision dosing application for prostate cancer chemotherapy","authors":"Claire Villettte, H. Mistry, F. Ortega, D. Orrell, F. Brightman, J. L. Millén, C. Chassagnole","doi":"10.1158/1538-7445.AM2019-677","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-677","url":null,"abstract":"The therapeutic window of chemotherapy drugs is commonly established at a population level and patient dose selection is often simply scaled with Body Surface Area. Due to large inter-individual physiological variability, this leads to a significant number of patients being under or over-dosed. While a limited number of precision dosing techniques exist to tailor patient-specific treatment, they typically require costly additonal tests which severly restrict their use in clinical practice. Focusing on the use of docetaxel in metastatic castrate-resistant prostate cancer, we have developed a demonstrator for precision dosing which relies only on routine blood tests that are already universally available in most health systems and could thus fit within the current clinical practice to improve patient outcome at a low cost. This tool was developed using publicly available data from Project Datasphere for the comparator arm of a phase III clinical trial for metastatic hormone-resistant prostate cancer (NCT00617669). This cohort includes 412 patients who were treated with Docetaxel between 2008 and 2011 in cycles of 21 days with weekly blood tests in the first cycle. A population PK/PD model for Docetaxel and leukocyte population was assembled based on literature [1,2]. Individual patient parameters including Docetaxel AUC were estimated by calibrating this model with weekly measured blood count using a Bayesian approach. Survival and toxicity Cox models were developed using estimated PK/PD parameters as well as biomarker levels. They allowed estimations of gains in prognostic as well as toxicity risks associated with modifying patient dose after the first chemotherapy cycle. These models will be made available through a web application to support clinicians in their decision to refine patient doses. Concordance levels of the order of 0.7 were obtained for the survival and toxicity models, with significant predictive variables including Docetaxel AUC, patient liver markers as well as PSA. Patients with low estimated hematologic toxicity (neutrophil count not dropping under 1 billion/L for more than 5 days) presented a median overall survival time of 461 days, against 563 days for patients with higher hematologic toxicity. Patients with low estimated Docetaxel AUC ( Citation Format: Claire Villettte, Hitesh Mistry, Fernando G. Ortega, David Orrell, Frances A. Brightman, Jim Millen, Christophe Chassagnole. A precision dosing application for prostate cancer chemotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 677.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130851918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Abstract 671: Evaluation of machine learning tools for cancer drug response prediction with genomic profile data and drug response data from PDX model studies 671:利用基因组谱数据和PDX模型研究的药物反应数据评估癌症药物反应预测的机器学习工具
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-671
Henry Y Gu, Jingjing Jiang
{"title":"Abstract 671: Evaluation of machine learning tools for cancer drug response prediction with genomic profile data and drug response data from PDX model studies","authors":"Henry Y Gu, Jingjing Jiang","doi":"10.1158/1538-7445.SABCS18-671","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-671","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"11 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132870946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 690: Optimization of biopsy scheduling in clinical studies of T cell bispecifics through an integrated modeling and simulation, digital pathology and machine learning approach 690:通过集成建模和仿真、数字病理学和机器学习方法优化T细胞双特异性临床研究中的活检安排
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-690
L. Hutchinson, A. Soubret, B. Ribba, J. Charoin, A. Phipps, R. Peck, O. Grimm
{"title":"Abstract 690: Optimization of biopsy scheduling in clinical studies of T cell bispecifics through an integrated modeling and simulation, digital pathology and machine learning approach","authors":"L. Hutchinson, A. Soubret, B. Ribba, J. Charoin, A. Phipps, R. Peck, O. Grimm","doi":"10.1158/1538-7445.AM2019-690","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-690","url":null,"abstract":"In the context of cancer immunotherapy clinical trials, baseline and on-treatment tumor biopsies may provide important insight into whether a treatment is working as expected, and furthermore whether efficacy is anticipated. For tumor-retained antibodies that perturb the behaviour of immune cells, such as T cell bispecific antibodies (TCBs), spatial information derived from biopsy images may be particularly insightful. On-treatment biopsies in clinical trials are usually scheduled at a time point that is considered convenient for the study design and when therapeutic effects, such as T cell infiltration, are expected to be distinguishable in tumor tissue. To our knowledge, there have been no attempts to investigate optimal scheduling of on-treatment biopsy sample collection using quantitative approaches due to lack of clinical data at a sufficiently diverse range of time points. Our integrated tissue pathology, disease modeling and machine learning workflow is designed to select the time point at which on-treatment biopsies could be most informative for making reliable predictions of response to treatment. Leveraging around 20 baseline and on-treatment digitized biopsy images from patients undergoing treatment with immune stimulating TCBs, we train a mathematical model to simulate tumor cell/T cell interactions in the tumor microenvironment. The mathematical model produces an enriched dataset of “virtual” biopsy images corresponding to predictions at intermediate time points. The virtual biopsies are evaluated based on their ability to predict treatment response. Specific mechanisms of action of bispecific antibodies, such as upregulation of T cell activation and/or proliferation, are taken into account in the structure of the mathematical model. The model is tuned and validated using machine learning techniques, and a reserved “test” dataset comprising images that were not used to estimate model parameters is used to evaluate model performance. Our workflow has the potential to inform clinical study design by promoting a scientific basis for the selection of an on-treatment biopsy schedule. Future applications of this workflow include identification of tissue properties that may contribute to inter-individual variability, and simulations of novel doses and schedules for combinations of immune-modulating cancer therapies. Citation Format: Lucy G. Hutchinson, Antoine Soubret, Benjamin Ribba, Jean-Eric Charoin, Alex Phipps, Richard Peck, Oliver Grimm. Optimization of biopsy scheduling in clinical studies of T cell bispecifics through an integrated modeling and simulation, digital pathology and machine learning approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 690.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133255252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 674: Predicting cellular response to therapy in breast cancer using mathematical modeling 摘要:利用数学模型预测乳腺癌细胞对治疗的反应
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-674
Wei He, Diane M. Demas, I. Conde, Yassi Fallah, W. Baumann, Ayesha N. Shajahan-Haq
{"title":"Abstract 674: Predicting cellular response to therapy in breast cancer using mathematical modeling","authors":"Wei He, Diane M. Demas, I. Conde, Yassi Fallah, W. Baumann, Ayesha N. Shajahan-Haq","doi":"10.1158/1538-7445.SABCS18-674","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-674","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"413 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134499261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书